GSGTF.US GenSight Biologics S.A

Healthcare Biotechnology USA Stocks
0.0800 USD
Close of Nov 14, 2026
0.0800 0.1901
Market cap
USD 19.6M
P/E
-
P/B
41.46x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is GSGTF.US undervalued?

Graham number

The Graham number of GenSight Biologics S.A cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GenSight Biologics S.A fundamental analysis

No fundamental analysis for GenSight Biologics S.A yet.

GenSight Biologics S.A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GenSight Biologics S.A

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of…

Full company profile